<p>Compass Therapeutics, Inc.（纳斯达克：CMPX - 获取免费报告）在三月份的空头头寸显著增长。截至 3 月 31 日，空头头寸总计为 6,620,000 股，比 3 月 15 日的 4,610,000 股增长了 43.6%。根据平均每日交易量 2,120,000 股，目前的覆盖天数比率为 3.1 天。目前，该股票的 8.2% 被卖空。</p>
<p>获取 <strong>Compass Therapeutics</strong> 的提醒：</p>
<h2>Compass Therapeutics 价格表现</h2>
<ul>
<li>分析师仍看好的三大高动量公司</li>
</ul>
<p>纳斯达克 CMPX 周五上涨 0.05 美元，达到 1.75 美元。该股票的交易量为 692,766 股，而其平均交易量为 859,566 股。Compass Therapeutics 的 1 年最低价为 0.77 美元，1 年最高价为 4.08 美元。该公司的市值为 2.42 亿美元，市盈率为-4.73，贝塔值为 1.40。该公司的 50 日移动平均价为 2.41 美元，200 日移动平均价为 2.09 美元。</p>
<p>Compass Therapeutics（纳斯达克：CMPX - 获取免费报告）最近于 2 月 27 日星期四发布了季度财报。该公司报告每股收益为（0.11 美元），低于分析师一致预期的（0.10 美元），差距为（0.01 美元）。研究分析师预测 Compass Therapeutics 在当前财政年度将发布-0.36 的每股收益。</p>
<h2>Compass Therapeutics 的内部活动</h2>
<p>在其他新闻中，董事 Carl L. Gordon 于 4 月 9 日星期三出售了 3,571,428 股 Compass Therapeutics 的股票，交易价格为每股 1.59 美元，总价值为 5,678,570.52 美元。该交易已在与证券交易委员会的法律文件中披露，可以通过 SEC 网站访问。此外，内部人士 Jonathan Anderman 于 4 月 7 日星期一购买了 20,000 股该公司的股票，交易价格为每股 1.54 美元，总交易额为 30,800.00 美元。购买后，该内部人士现在直接拥有 21,000 股公司股票，价值 32,340 美元。此交易代表其持股增加了 2,000.00%。该购买的披露信息可以在这里找到。28.50% 的股票目前由公司内部人士持有。</p>
<h2>对 Compass Therapeutics 的对冲基金看法</h2>
<p>几家对冲基金和其他机构投资者最近对 CMPX 的持仓进行了调整。SG Americas Securities LLC 在第一季度将其在 Compass Therapeutics 的持仓增加了 138.2%。SG Americas Securities LLC 目前拥有 940,784 股该公司的股票，价值 1,787,000 美元，此前在上个季度增持了 545,767 股。Simplicity Wealth LLC 在第一季度购买了 Compass Therapeutics 的新头寸，价值 88,000 美元。Squarepoint Ops LLC 在第四季度获得了 Compass Therapeutics 的新头寸，价值 35,000 美元。Tang Capital Management LLC 在第四季度将其在 Compass Therapeutics 的持仓增加了 225.4%。Tang Capital Management LLC 目前拥有 5,900,000 股该公司的股票，价值 8,555,000 美元，此前在上个季度增持了 4,087,005 股。最后，ProShare Advisors LLC 在第四季度将其在 Compass Therapeutics 的持仓增加了 49.0%。ProShare Advisors LLC 目前拥有 28,722 股该公司的股票，价值 42,000 美元，此前在上个季度增持了 9,451 股。68.43% 的股票目前由机构投资者和对冲基金持有。</p>
<h2>分析师评级变动</h2>
<p>一些分析师最近对 CMPX 股票发表了评论。Leerink Partners 在 4 月 1 日星期二的研究报告中将 Compass Therapeutics 的评级从 “持有” 上调至 “强力买入”。D. Boral Capital 在 4 月 1 日星期二重申了 “买入” 评级，并对 Compass Therapeutics 的股票设定了 32.00 美元的目标价。Leerink Partners 在 4 月 2 日星期三将 Compass Therapeutics 的股票评级从 “市场表现” 上调至 “跑赢大盘”，并将其目标价从 4.00 美元提高至 6.00 美元。HC Wainwright 在 4 月 4 日星期五将 Compass Therapeutics 的目标价从 10.00 美元提高至 24.00 美元，并给予该公司 “买入” 评级。最后，Guggenheim 在 4 月 2 日星期三重申了 “买入” 评级，并对 Compass Therapeutics 的股票设定了 12.00 美元的目标价。八位研究分析师对该股票给予了买入评级，一位分析师给予了强力买入评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “买入”，平均目标价为 13.38 美元。</p>
<p><strong>获取我们关于 Compass Therapeutics 的最新报告</strong></p>
<h2>关于 Compass Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Compass Therapeutics, Inc.是一家临床阶段的肿瘤学生物制药公司，专注于开发基于抗体的治疗方法，以治疗美国的各种人类疾病。该公司的主要产品候选包括 CTX-009，一种双特异性抗体，阻断 Delta-like ligand 4（Notch-1 的配体）和血管内皮生长因子 A 信号通路，这些通路对血管生成和肿瘤血管化至关重要；以及 CTX-471，一种 IgG4 单克隆抗体，是 CD137 的激动剂，CD137 是免疫细胞上的一个关键共刺激受体。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 Compass Therapeutics 更好</li>
<li>在哪里可以找到财报电话会议记录</li>
<li>三只中型到大型股票宣布了重大回购</li>
<li>金融服务股票投资</li>
<li>这三只股票在过去 12 个月的股东收益巨大</li>
<li>如何投资小型股</li>
<li>知名对冲基金收购 HPE 的巨大股份：现在值得购买吗？</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Compass Therapeutics 吗？</h2>
<p>在考虑 Compass Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Compass Therapeutics 并不在名单上。</p>
<p>虽然 Compass Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CMPX

<p>Compass Therapeutics, Inc.（纳斯达克代码：CMPX）在三月份的空头头寸增加了 43.6%，总计达到 6,620,000 股。该公司约有 8.2% 的股份被做空，基于每日平均交易量 2,120,000 股，空头头寸比率为 3.1 天。该股票交易价格为 1.75 美元，市值为 2.42 亿美元。最近的内部交易包括董事 Carl L. Gordon 的大额出售和内部人士 Jonathan Anderman 的购买。分析师们已上调了该股票的评级，多位分析师设定了更高的价格目标</p>

<p>Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 6,620,000 shares, a growth of 43.6% from the March 15th total of 4,610,000 shares. Based on an average daily trading volume, of 2,120,000 shares, the days-to-cover ratio is presently 3.1 days. Currently, 8.2% of the shares of the stock are sold short.</p>
<div class="lb-trans"><p>Compass Therapeutics, Inc.（纳斯达克：CMPX - 获取免费报告）在三月份的空头头寸显著增长。截至 3 月 31 日，空头头寸总计为 6,620,000 股，比 3 月 15 日的 4,610,000 股增长了 43.6%。根据平均每日交易量 2,120,000 股，目前的覆盖天数比率为 3.1 天。目前，该股票的 8.2% 被卖空。</p>
</div><p>Get <strong>Compass Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Compass Therapeutics</strong> 的提醒：</p>
</div><h2>Compass Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Compass Therapeutics 价格表现</h2>
</div><ul>
<li>Top 3 High-Momentum Companies Analysts Are Still Bullish On</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师仍看好的三大高动量公司</li>
</ul>
</div><p>NASDAQ CMPX traded up $0.05 on Friday, reaching $1.75. The stock had a trading volume of 692,766 shares, compared to its average volume of 859,566. Compass Therapeutics has a 1-year low of $0.77 and a 1-year high of $4.08. The company has a market cap of $242.00 million, a P/E ratio of -4.73 and a beta of 1.40. The firm has a fifty day moving average of $2.41 and a two-hundred day moving average of $2.09.</p>
<div class="lb-trans"><p>纳斯达克 CMPX 周五上涨 0.05 美元，达到 1.75 美元。该股票的交易量为 692,766 股，而其平均交易量为 859,566 股。Compass Therapeutics 的 1 年最低价为 0.77 美元，1 年最高价为 4.08 美元。该公司的市值为 2.42 亿美元，市盈率为-4.73，贝塔值为 1.40。该公司的 50 日移动平均价为 2.41 美元，200 日移动平均价为 2.09 美元。</p>
</div><p>Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01). Research analysts predict that Compass Therapeutics will post -0.36 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Compass Therapeutics（纳斯达克：CMPX - 获取免费报告）最近于 2 月 27 日星期四发布了季度财报。该公司报告每股收益为（0.11 美元），低于分析师一致预期的（0.10 美元），差距为（0.01 美元）。研究分析师预测 Compass Therapeutics 在当前财政年度将发布-0.36 的每股收益。</p>
</div><h2>Insider Activity at Compass Therapeutics</h2>
<div class="lb-trans"><h2>Compass Therapeutics 的内部活动</h2>
</div><p>In other news, Director Carl L. Gordon sold 3,571,428 shares of Compass Therapeutics stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total value of $5,678,570.52. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Also, insider Jonathan Anderman purchased 20,000 shares of the business's stock in a transaction dated Monday, April 7th. The shares were purchased at an average cost of $1.54 per share, for a total transaction of $30,800.00. Following the purchase, the insider now directly owns 21,000 shares of the company's stock, valued at $32,340. This trade represents a 2,000.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 28.50% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他新闻中，董事 Carl L. Gordon 于 4 月 9 日星期三出售了 3,571,428 股 Compass Therapeutics 的股票，交易价格为每股 1.59 美元，总价值为 5,678,570.52 美元。该交易已在与证券交易委员会的法律文件中披露，可以通过 SEC 网站访问。此外，内部人士 Jonathan Anderman 于 4 月 7 日星期一购买了 20,000 股该公司的股票，交易价格为每股 1.54 美元，总交易额为 30,800.00 美元。购买后，该内部人士现在直接拥有 21,000 股公司股票，价值 32,340 美元。此交易代表其持股增加了 2,000.00%。该购买的披露信息可以在这里找到。28.50% 的股票目前由公司内部人士持有。</p>
</div><h2>Hedge Funds Weigh In On Compass Therapeutics</h2>
<div class="lb-trans"><h2>对 Compass Therapeutics 的对冲基金看法</h2>
</div><p>Several hedge funds and other institutional investors have recently made changes to their positions in CMPX. SG Americas Securities LLC grew its position in Compass Therapeutics by 138.2% in the first quarter. SG Americas Securities LLC now owns 940,784 shares of the company's stock valued at $1,787,000 after acquiring an additional 545,767 shares during the last quarter. Simplicity Wealth LLC bought a new position in shares of Compass Therapeutics in the 1st quarter worth $88,000. Squarepoint Ops LLC acquired a new position in Compass Therapeutics during the fourth quarter worth $35,000. Tang Capital Management LLC lifted its position in Compass Therapeutics by 225.4% in the 4th quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company's stock valued at $8,555,000 after acquiring an additional 4,087,005 shares in the last quarter. Finally, ProShare Advisors LLC boosted its position in shares of Compass Therapeutics by 49.0% during the fourth quarter. ProShare Advisors LLC now owns 28,722 shares of the company's stock valued at $42,000 after buying an additional 9,451 shares during the last quarter. 68.43% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近对 CMPX 的持仓进行了调整。SG Americas Securities LLC 在第一季度将其在 Compass Therapeutics 的持仓增加了 138.2%。SG Americas Securities LLC 目前拥有 940,784 股该公司的股票，价值 1,787,000 美元，此前在上个季度增持了 545,767 股。Simplicity Wealth LLC 在第一季度购买了 Compass Therapeutics 的新头寸，价值 88,000 美元。Squarepoint Ops LLC 在第四季度获得了 Compass Therapeutics 的新头寸，价值 35,000 美元。Tang Capital Management LLC 在第四季度将其在 Compass Therapeutics 的持仓增加了 225.4%。Tang Capital Management LLC 目前拥有 5,900,000 股该公司的股票，价值 8,555,000 美元，此前在上个季度增持了 4,087,005 股。最后，ProShare Advisors LLC 在第四季度将其在 Compass Therapeutics 的持仓增加了 49.0%。ProShare Advisors LLC 目前拥有 28,722 股该公司的股票，价值 42,000 美元，此前在上个季度增持了 9,451 股。68.43% 的股票目前由机构投资者和对冲基金持有。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>A number of analysts have recently commented on CMPX shares. Leerink Partnrs raised Compass Therapeutics from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Tuesday, April 1st. D. Boral Capital restated a &#34;buy&#34; rating and issued a $32.00 price target on shares of Compass Therapeutics in a report on Tuesday, April 1st. Leerink Partners upgraded shares of Compass Therapeutics from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and increased their target price for the stock from $4.00 to $6.00 in a report on Wednesday, April 2nd. HC Wainwright increased their price target on Compass Therapeutics from $10.00 to $24.00 and gave the company a &#34;buy&#34; rating in a research report on Friday, April 4th. Finally, Guggenheim reissued a &#34;buy&#34; rating and issued a $12.00 price objective on shares of Compass Therapeutics in a research report on Wednesday, April 2nd. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of &#34;Buy&#34; and an average price target of $13.38.</p>
<div class="lb-trans"><p>一些分析师最近对 CMPX 股票发表了评论。Leerink Partners 在 4 月 1 日星期二的研究报告中将 Compass Therapeutics 的评级从 “持有” 上调至 “强力买入”。D. Boral Capital 在 4 月 1 日星期二重申了 “买入” 评级，并对 Compass Therapeutics 的股票设定了 32.00 美元的目标价。Leerink Partners 在 4 月 2 日星期三将 Compass Therapeutics 的股票评级从 “市场表现” 上调至 “跑赢大盘”，并将其目标价从 4.00 美元提高至 6.00 美元。HC Wainwright 在 4 月 4 日星期五将 Compass Therapeutics 的目标价从 10.00 美元提高至 24.00 美元，并给予该公司 “买入” 评级。最后，Guggenheim 在 4 月 2 日星期三重申了 “买入” 评级，并对 Compass Therapeutics 的股票设定了 12.00 美元的目标价。八位研究分析师对该股票给予了买入评级，一位分析师给予了强力买入评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “买入”，平均目标价为 13.38 美元。</p>
</div><p><strong>Get Our Latest Report on Compass Therapeutics</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Compass Therapeutics 的最新报告</strong></p>
</div><h2>About Compass Therapeutics</h2>
<div class="lb-trans"><h2>关于 Compass Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.</p>
<div class="lb-trans"><p>Compass Therapeutics, Inc.是一家临床阶段的肿瘤学生物制药公司，专注于开发基于抗体的治疗方法，以治疗美国的各种人类疾病。该公司的主要产品候选包括 CTX-009，一种双特异性抗体，阻断 Delta-like ligand 4（Notch-1 的配体）和血管内皮生长因子 A 信号通路，这些通路对血管生成和肿瘤血管化至关重要；以及 CTX-471，一种 IgG4 单克隆抗体，是 CD137 的激动剂，CD137 是免疫细胞上的一个关键共刺激受体。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Compass Therapeutics</li>
<li>Where to Find Earnings Call Transcripts</li>
<li>3 Mid-Cap to Mega-Cap Stocks Have Announced Significant Buybacks</li>
<li>Financial Services Stocks Investing</li>
<li>These 3 Stocks Have Huge Last 12 Months Shareholder Yields</li>
<li>How to Invest in Small Cap Stocks</li>
<li>Prominent Hedge Fund Acquires Huge Stake in HPE: Is It a Buy Now?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Compass Therapeutics 更好</li>
<li>在哪里可以找到财报电话会议记录</li>
<li>三只中型到大型股票宣布了重大回购</li>
<li>金融服务股票投资</li>
<li>这三只股票在过去 12 个月的股东收益巨大</li>
<li>如何投资小型股</li>
<li>知名对冲基金收购 HPE 的巨大股份：现在值得购买吗？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Compass Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Compass Therapeutics 吗？</h2>
</div><p>Before you consider Compass Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Compass Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compass Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Compass Therapeutics 并不在名单上。</p>
</div><p>While Compass Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Compass Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Compass Therapeutics, Inc.（纳斯达克代码：CMPX）的空头头寸增加了 43.6%